Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice

BACKGROUND: Vaccines that block human-to-mosquito Plasmodium transmission are needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for decades. We reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced serum functional activity i...

Descripción completa

Detalles Bibliográficos
Autores principales: Healy, Sara A., Anderson, Charles, Swihart, Bruce J., Mwakingwe, Agnes, Gabriel, Erin E., Decederfelt, Hope, Hobbs, Charlotte V., Rausch, Kelly M., Zhu, Daming, Muratova, Olga, Herrera, Raul, Scaria, Puthupparampil V., MacDonald, Nicholas J., Lambert, Lynn E., Zaidi, Irfan, Coelho, Camila H., Renn, Jonathan P., Wu, Yimin, Narum, David L., Duffy, Patrick E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011888/
https://www.ncbi.nlm.nih.gov/pubmed/33561016
http://dx.doi.org/10.1172/JCI146221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011888/
https://www.ncbi.nlm.nih.gov/pubmed/33561016
http://dx.doi.org/10.1172/JCI146221

Ejemplares similares